SG10201501062SA - Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same - Google Patents

Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same

Info

Publication number
SG10201501062SA
SG10201501062SA SG10201501062SA SG10201501062SA SG10201501062SA SG 10201501062S A SG10201501062S A SG 10201501062SA SG 10201501062S A SG10201501062S A SG 10201501062SA SG 10201501062S A SG10201501062S A SG 10201501062SA SG 10201501062S A SG10201501062S A SG 10201501062SA
Authority
SG
Singapore
Prior art keywords
compositions
methods
same
isoindoline derivatives
arylmethoxy isoindoline
Prior art date
Application number
SG10201501062SA
Other languages
English (en)
Inventor
Hon-Wah Man
George W Muller
Alexander Ruchelman
Ehab M Khalil
Roger Shen-Chu Chen
Weihong Zhang
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of SG10201501062SA publication Critical patent/SG10201501062SA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • AIDS & HIV (AREA)
  • Anesthesiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
SG10201501062SA 2010-02-11 2011-02-10 Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same SG10201501062SA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US30361810P 2010-02-11 2010-02-11

Publications (1)

Publication Number Publication Date
SG10201501062SA true SG10201501062SA (en) 2015-04-29

Family

ID=43708752

Family Applications (3)

Application Number Title Priority Date Filing Date
SG10201501062SA SG10201501062SA (en) 2010-02-11 2011-02-10 Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same
SG2012059259A SG183257A1 (en) 2010-02-11 2011-02-10 Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same
SG10202012179RA SG10202012179RA (en) 2010-02-11 2011-02-10 Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same

Family Applications After (2)

Application Number Title Priority Date Filing Date
SG2012059259A SG183257A1 (en) 2010-02-11 2011-02-10 Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same
SG10202012179RA SG10202012179RA (en) 2010-02-11 2011-02-10 Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same

Country Status (32)

Country Link
US (8) US8518972B2 (hu)
EP (6) EP3202460B1 (hu)
JP (5) JP2013519675A (hu)
KR (2) KR101931468B1 (hu)
CN (2) CN102822165B (hu)
AR (1) AR081058A1 (hu)
AU (1) AU2011215877C1 (hu)
CA (1) CA2787823C (hu)
CO (1) CO6571916A2 (hu)
CR (1) CR20120414A (hu)
CY (3) CY1119177T1 (hu)
DK (3) DK3202460T3 (hu)
EC (1) ECSP12012098A (hu)
ES (5) ES2638517T3 (hu)
HR (3) HRP20171078T1 (hu)
HU (3) HUE033009T2 (hu)
IL (2) IL220992A (hu)
LT (3) LT3202460T (hu)
ME (2) ME02766B (hu)
MX (3) MX2012009237A (hu)
NI (1) NI201200132A (hu)
NZ (3) NZ601289A (hu)
PH (1) PH12014501082B1 (hu)
PL (3) PL3202461T3 (hu)
PT (3) PT3202461T (hu)
RS (3) RS59275B1 (hu)
RU (1) RU2567753C2 (hu)
SG (3) SG10201501062SA (hu)
SI (3) SI3202460T1 (hu)
TR (1) TR201903027T4 (hu)
UA (2) UA114856C2 (hu)
WO (1) WO2011100380A1 (hu)

Families Citing this family (128)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120134969A1 (en) 2009-05-25 2012-05-31 Hiroshi Handa Pharmaceutical composition containing nuclear factor involved in proliferation and differentiation of central neuronal cells
LT3202460T (lt) 2010-02-11 2019-10-10 Celgene Corporation Arilmetoksi izoindolino dariniai ir kompozicijos, apimantys ir jų panaudojimo būdus
EP2699091B1 (en) * 2011-03-28 2017-06-21 DeuteRx, LLC 2',6'-dioxo-3'-deutero-piperdin-3-yl-isoindoline compounds
EP2702410A2 (en) 2011-04-29 2014-03-05 Celgene Corporation Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor
CA2877736C (en) 2012-06-29 2021-12-07 Celgene Corporation Methods for determining drug efficacy using cereblon-associated proteins
US20140343058A1 (en) * 2012-08-09 2014-11-20 Celgene Corporation Treatment of systemic lupus erythematosus
EP3949968A1 (en) * 2012-08-09 2022-02-09 Celgene Corporation Methods of treating cancer using 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione
NZ628077A (en) 2012-08-09 2017-04-28 Celgene Corp Treatment of immune-related and inflammatory diseases
US20150038511A1 (en) * 2012-08-09 2015-02-05 Celgene Corporation Treatment of immune-related and inflammatory diseases
ES2885769T3 (es) * 2012-08-09 2021-12-15 Celgene Corp Una forma sólida de clorhidrato de (s)-3-(4-((4-morpholinometil)bencil)oxi)-1-oxoisoindolin-2-il)piperidina-2,6-diona
WO2014025978A1 (en) * 2012-08-09 2014-02-13 Celgene Corporation Processes for the preparation of (s)-3-4-((4-(morpholinomethyl) benzyl)oxy)-1-oxoisoindolin-2-yl) piperidine-2,6-dione and pharmaceutically acceptable forms thereof
US9587281B2 (en) 2012-08-14 2017-03-07 Celgene Corporation Cereblon isoforms and their use as biomarkers for therapeutic treatment
CA2884103A1 (en) * 2012-09-10 2014-03-13 Celgene Corporation Methods for the treatment of locally advanced breast cancer
AU2013204922B2 (en) 2012-12-20 2015-05-14 Celgene Corporation Chimeric antigen receptors
CA2935495C (en) 2013-01-14 2021-04-20 Deuterx, Llc 3-(5-substituted-4-oxoquinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives
US9695145B2 (en) 2013-01-22 2017-07-04 Celgene Corporation Processes for the preparation of isotopologues of 3-(4-((4- morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and pharmaceutically acceptable salts thereof
CA2941560A1 (en) 2013-03-14 2014-09-25 Deuterx, Llc 3-(substituted-4-oxo-quinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives
CN105518018B (zh) 2013-03-15 2020-04-03 细胞基因公司 修饰的t淋巴细胞
KR102223060B1 (ko) 2013-04-17 2021-03-05 시그날 파마소티칼 엘엘씨 암 치료를 위한 TOR 키나제 억제제 및 ＩＭｉＤ 화합물을 포함하는 조합요법
UA117141C2 (uk) * 2013-10-08 2018-06-25 Селджин Корпорейшн Склади (s)-3-(4-((4-(морфолінометил)бензил)оксі)-1-оксоізоіндолін-2-іл)піперидин-2,6-діону
BR112016012795A2 (pt) * 2013-12-06 2017-08-08 Celgene Corp Métodos para a determinação da eficácia do fármaco para o tratamento de linfoma difuso de grandes células b, mieloma múltiplo e cânceres mieloides
KR102320082B1 (ko) * 2014-04-14 2021-10-29 아비나스 오퍼레이션스, 인코포레이티드 단백질분해의 이미드-기초된 조절인자 및 연관된 이용 방법
TWI745271B (zh) 2014-05-19 2021-11-11 美商西建公司 全身紅斑性狼瘡之治療
JP6640126B2 (ja) 2014-06-27 2020-02-05 セルジーン コーポレイション セレブロン及び他のｅ３ユビキチンリガーゼの立体構造の変化を誘導するための組成物及び方法
JP6889101B2 (ja) 2014-08-07 2021-06-18 キャリセラ バイオサイエンシーズ， インコーポレイテッド グルタミナーゼ阻害剤の結晶形態
HUE061382T2 (hu) 2014-08-22 2023-06-28 Celgene Corp Eljárás myeloma multiplex kezelésére immunomoduláló vegyületekkel, antestekkel kombinálva
PL3214081T3 (pl) * 2014-10-30 2021-04-06 Kangpu Biopharmaceuticals, Ltd. Pochodna izoindoliny, półprodukt, sposób wytwarzania, kompozycja farmaceutyczna i ich zastosowanie
US20170327469A1 (en) 2015-01-20 2017-11-16 Arvinas, Inc. Compounds and methods for the targeted degradation of androgen receptor
US11352351B2 (en) 2015-01-20 2022-06-07 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor
EP3302482A4 (en) 2015-06-05 2018-12-19 Arvinas, Inc. Tank-binding kinase-1 protacs and associated methods of use
CN113087763A (zh) * 2015-07-21 2021-07-09 伊缪诺金公司 制备细胞毒性苯并二氮杂䓬衍生物的方法
US9809603B1 (en) 2015-08-18 2017-11-07 Deuterx, Llc Deuterium-enriched isoindolinonyl-piperidinonyl conjugates and oxoquinazolin-3(4H)-yl-piperidinonyl conjugates and methods of treating medical disorders using same
EP3337476A4 (en) 2015-08-19 2019-09-04 Arvinas, Inc. COMPOUNDS AND METHODS FOR TARGETED DEGRADATION OF PROTEINS CONTAINING BROMODOMAIN
EP3357513B1 (en) * 2015-09-29 2023-10-25 Kangpu Biopharmaceuticals, Ltd. Pharmaceutical composition and application thereof
US10830762B2 (en) 2015-12-28 2020-11-10 Celgene Corporation Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases
EP3440082A1 (en) * 2016-04-06 2019-02-13 The Regents of The University of Michigan Monofunctional intermediates for ligand-dependent target protein degradation
SG11201808729WA (en) * 2016-04-12 2018-11-29 Univ Michigan Regents Bet protein degraders
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
KR102173463B1 (ko) 2016-10-11 2020-11-04 아비나스 오퍼레이션스, 인코포레이티드 안드로겐 수용체의 표적 분해용 화합물 및 방법
US20190255041A1 (en) 2016-10-28 2019-08-22 Icahn School Of Medicine At Mount Sinai Compositions and methods for treating ezh2-mediated cancer
AU2017367872B2 (en) 2016-11-01 2022-03-31 Arvinas, Inc. Tau-protein targeting protacs and associated methods of use
JP7267914B2 (ja) 2016-11-02 2023-05-02 エンクマフ エスアーエールエル Ｂｃｍａ及びｃｄ３に対する二重特異性抗体、及び多発性骨髄腫を治療するために併用して使用される免疫療法薬
LT3689868T (lt) 2016-12-01 2023-12-27 Arvinas Operations, Inc. Tetrahidronaftaleno ir tetrahidroizochinolino dariniai kaip estrogenų receptorių destruktoriai
JP2020514252A (ja) 2016-12-08 2020-05-21 アイカーン スクール オブ メディスン アット マウント シナイ Ｃｄｋ４／６媒介性がんを治療するための組成物および方法
ES2884064T3 (es) * 2016-12-16 2021-12-10 Kangpu Biopharmaceuticals Ltd Composición combinada que comprende un compuesto benzoheterocíclico y un modulador de la vía de los receptores androgénicos y usos de la misma
WO2018118598A1 (en) 2016-12-23 2018-06-28 Arvinas, Inc. Compounds and methods for the targeted degradation of fetal liver kinase polypeptides
BR112019012878A2 (pt) 2016-12-23 2019-11-26 Arvinas Operations Inc compostos e métodos para a degradação alvo de polipeptídos de fibrossarcoma rapidamente acelerados
US11173211B2 (en) 2016-12-23 2021-11-16 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides
US10994015B2 (en) 2016-12-23 2021-05-04 Arvinas Operations, Inc. EGFR proteolysis targeting chimeric molecules and associated methods of use
US11191741B2 (en) 2016-12-24 2021-12-07 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide
CN117551089A (zh) 2017-01-26 2024-02-13 阿尔维纳斯运营股份有限公司 雌激素受体蛋白水解调节剂及相关使用方法
JP7062010B2 (ja) * 2017-01-27 2022-05-02 セルジーン コーポレイション ３－（１－オキソ－４－（（４－（（３－オキソモルホリノ）メチル）ベンジル）オキシ）イソインドリン－２－イル）ピペリジン－２，６－ジオン及びそのアイソトポログ
EP3577459A4 (en) 2017-02-03 2020-12-16 Celgene Corporation METHOD OF MEASURING THE AFFINITY OF SMALL MOLECULES FOR CEREBLON
CN110248662B (zh) 2017-02-13 2022-08-16 康朴生物医药技术（上海）有限公司 一种治疗前列腺癌的组合、药物组合物及治疗方法
CN108929307A (zh) * 2017-05-22 2018-12-04 苏州偶领生物医药有限公司 一类异吲哚酮-酰亚胺环-1,3-二酮-2-烯化合物、其组合物和用途
AU2018301335B2 (en) * 2017-07-10 2022-09-15 Celgene Corporation Antiproliferative compounds and methods of use thereof
EP3672939A1 (en) 2017-08-21 2020-07-01 Celgene Corporation Processes for preparation of (s)-tert-butyl 4,5-diamino-5-oxopentanoate
US10513515B2 (en) 2017-08-25 2019-12-24 Biotheryx, Inc. Ether compounds and uses thereof
AU2018336171B2 (en) 2017-09-22 2023-01-05 Jubilant Epipad LLC Heterocyclic compounds as PAD inhibitors
CA3076476A1 (en) 2017-10-18 2019-04-25 Jubilant Epipad LLC Imidazo-pyridine compounds as pad inhibitors
WO2019087214A1 (en) 2017-11-06 2019-05-09 Jubilant Biosys Limited Pyrimidine derivatives as inhibitors of pd1/pd-l1 activation
WO2019099926A1 (en) 2017-11-17 2019-05-23 Arvinas, Inc. Compounds and methods for the targeted degradation of interleukin-1 receptor-associated kinase 4 polypeptides
KR20200092346A (ko) 2017-11-24 2020-08-03 주빌런트 에피스크라이브 엘엘씨 Prmt5 억제제로서의 헤테로사이클릭 화합물
US11299485B2 (en) 2018-01-25 2022-04-12 Fujimoto Co., Ltd. Thiophene derivative and use thereof
WO2019148055A1 (en) 2018-01-26 2019-08-01 Yale University Imide-based modulators of proteolysis and methods of use
AU2019223076A1 (en) 2018-02-21 2020-10-08 Celgene Corporation BCMA-binding antibodies and uses thereof
US11472799B2 (en) 2018-03-06 2022-10-18 Icahn School Of Medicine At Mount Sinai Serine threonine kinase (AKT) degradation / disruption compounds and methods of use
JP7279063B6 (ja) 2018-03-13 2024-02-15 ジュビラント プローデル エルエルシー Ｐｄ１／ｐｄ－ｌ１相互作用／活性化の阻害剤としての二環式化合物
AU2019249231B2 (en) 2018-04-04 2022-04-21 Arvinas Operations, Inc. Modulators of proteolysis and associated methods of use
CA3096404A1 (en) 2018-04-23 2019-10-31 Celgene Corporation Substituted 4-aminoisoindoline-1,3-dione compounds and their use for treating lymphoma
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
WO2020012334A1 (en) * 2018-07-10 2020-01-16 Novartis Ag 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and their use in the treatment of ikaros family zinc finger 2 (ikzf2)-dependent diseases
CA3106239A1 (en) 2018-07-27 2020-01-30 Biotheryx, Inc. Bifunctional compounds as cdk modulators
JP7297053B2 (ja) 2018-08-20 2023-06-23 アルビナス・オペレーションズ・インコーポレイテッド 神経変性疾患を治療するためのｅ３ユビキチンリガーゼ結合活性を有するキメラ（ｐｒｏｔａｃ）化合物を標的とし、アルファ－シヌクレインタンパク質を標的とするタンパク質分解
JP7098825B2 (ja) * 2018-09-07 2022-07-11 メッドシャイン ディスカバリー インコーポレイテッド 三環式置換ピペリジンジオン類化合物
CN110963994B (zh) * 2018-09-30 2022-02-08 中国科学院上海药物研究所 异吲哚啉类化合物、其制备方法、药物组合物及用途
JP7466549B2 (ja) 2018-10-01 2024-04-12 セルジーン コーポレイション がん治療のための併用療法
JP2022512971A (ja) 2018-11-08 2022-02-07 ジュノー セラピューティクス インコーポレイテッド 処置およびｔ細胞調節のための方法および併用
US20230045737A1 (en) * 2018-12-05 2023-02-09 Vividion Therapeutics, Inc. Substituted isoindolinones as modulators of cereblon-mediated neo-substrate recruitment
WO2020114482A1 (zh) 2018-12-06 2020-06-11 中国科学院上海药物研究所 一类异吲哚啉类化合物、其制备方法、药物组合物及其应用
EA202191904A1 (ru) 2019-01-09 2021-10-04 Селджин Корпорейшн Фармацевтические композиции, содержащие (s)-4-(4-(4-(((2-(2,6-диоксопиперидин-3-ил)-1-оксоизоиндолин-4-ил)окси)метил)бензил)пиперазин-1-ил)-3-фторбензонитрил и способы их применения
SG11202107413YA (en) 2019-01-09 2021-08-30 Celgene Corp Antiproliferative compounds and second active agents for use in treating multiple myeloma
CN114394954B (zh) 2019-01-09 2024-04-02 细胞基因公司 包含氧代异吲哚化合物及其盐的固体形式，以及包含它们的组合物和它们的使用方法
AR119715A1 (es) * 2019-04-12 2022-01-05 Celgene Corp Métodos para tratar linfoma no hodgkin con el uso de 2-(2,6-dioxopiperidin-3-il)-4-((2-fluoro-4-((3-morfolinoazetidin-1-il)metil)bencil)amino)isoindolin-1,3-diona
WO2021011913A1 (en) 2019-07-17 2021-01-21 Arvinas Operations, Inc. Tau-protein targeting compounds and associated methods of use
EP4054622A1 (en) 2019-11-05 2022-09-14 Celgene Corporation Uses of anti-bcma chimeric antigen receptors
US20220401483A1 (en) 2019-11-07 2022-12-22 Juno Therapeutics, Inc. Combination of a t cell therapy and (s)-3-[4-(4-morpholin-4-ylmethyl-benzyloxy)-l-oxo-l,3-dihydro-isoindol-2-yl]-piperidine-2,6-dione
KR20220106801A (ko) 2019-11-27 2022-07-29 캡터 테라퓨틱스 에스.에이. 세레블론에 결합하는 피페리딘-2,6-디온 유도체 및 이의 사용 방법
US20230065745A1 (en) 2019-11-27 2023-03-02 Captor Therapeutics S.A. Piperidine-2,6-dione derivatives which bind to cereblon, and methods of use thereof
WO2021113212A1 (en) 2019-12-02 2021-06-10 Celgene Corporation Therapy for the treatment of cancer
KR20220118460A (ko) 2019-12-12 2022-08-25 액큐타 바이오테크놀로지 인코포레이티드 에스트로겐 수용체 분해 활성을 갖는 신규한 크로만 유도체 및 이의 용도
WO2021127190A1 (en) * 2019-12-17 2021-06-24 Kymera Therapeutics, Inc. Irak degraders and uses thereof
AU2020410514A1 (en) * 2019-12-18 2022-06-30 Novartis Ag 3-(5-methoxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
EP4077309A1 (en) 2019-12-19 2022-10-26 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor
EP4081518A4 (en) 2019-12-23 2023-12-27 Accutar Biotechnology, Inc. COMBINATIONS OF ESTROGEN RECEPTOR DEGRADERS AND CYCLINE-DEPENDENT KINASE INHIBITORS FOR THE TREATMENT OF CANCER
JP7408819B2 (ja) * 2020-01-20 2024-01-05 カング バイオファーマシューティカルズ リミテッド イソインドリン誘導体、並びにその医薬組成物及び使用
KR20220145366A (ko) * 2020-02-25 2022-10-28 상하이테크 유니버시티 글루타르이미드 골격을 기초로 하는 화합물 및 그 응용
US11897930B2 (en) 2020-04-28 2024-02-13 Anwita Biosciences, Inc. Interleukin-2 polypeptides and fusion proteins thereof, and their pharmaceutical compositions and therapeutic applications
BR112022020673A2 (pt) 2020-04-30 2023-01-24 Bristol Myers Squibb Co Métodos de tratamento de eventos adversos relacionados à citocina
CN115916191A (zh) 2020-06-25 2023-04-04 新基公司 用组合疗法治疗癌症的方法
CN113896711A (zh) * 2020-07-06 2022-01-07 北京诺诚健华医药科技有限公司 杂环类免疫调节剂
WO2022017365A1 (zh) * 2020-07-20 2022-01-27 江苏恒瑞医药股份有限公司 含硫异吲哚啉类衍生物、其制备方法及其在医药上的应用
IL300308A (en) 2020-08-03 2023-04-01 Captor Therapeutics S A Low molecular weight protein complexes and their applications
WO2022051495A1 (en) * 2020-09-02 2022-03-10 Ann And Robert H. Lurie Children's Hospital Of Chicago Methods and compositions for the treatment of pulmonary hypertension and cancer
US20230364230A1 (en) 2020-09-11 2023-11-16 Engmab Sàrl Combination therapy for cancer
WO2022066580A1 (en) * 2020-09-23 2022-03-31 Kinnate Biopharma Inc. Raf degrading compounds
CN116234553A (zh) * 2020-10-02 2023-06-06 新基公司 治疗系统性红斑狼疮的方法和作为对疗法临床敏感性的预测指标的生物标志物的用途
KR20230113755A (ko) 2020-11-04 2023-08-01 셀진 코포레이션 선행 항암 알킬화제 요법을 받은 환자에서의 car t 세포 요법
CN112174976A (zh) * 2020-11-19 2021-01-05 江西中医药大学 从水芹菜中分离的二苯并呋喃型木脂素及其方法和在抗痛风性关节炎上的用途
WO2022146151A1 (en) 2020-12-30 2022-07-07 Captor Therapeutics S.A. Novel compounds which bind to cereblon, and methods of use thereof
WO2022148358A1 (zh) * 2021-01-05 2022-07-14 江苏恒瑞医药股份有限公司 稠杂环基取代的环己二酰亚胺衍生物、其制备方法及其在医药上的应用
WO2022152821A1 (en) 2021-01-13 2022-07-21 Monte Rosa Therapeutics Ag Isoindolinone compounds
UY39671A (es) * 2021-03-15 2022-10-31 Novartis Ag Derivados de pirazolopiridina y sus usos.
IL305956A (en) * 2021-03-31 2023-11-01 Duke Street Bio Ltd Pharmaceutical material
EP4323352A1 (en) 2021-04-16 2024-02-21 Arvinas Operations, Inc. Modulators of bcl6 proteolysis and associated methods of use
WO2022255889A1 (en) 2021-06-01 2022-12-08 Captor Therapeutics S.A. Compounds which bind to cereblon, and use thereof
WO2022255890A1 (en) 2021-06-01 2022-12-08 Captor Therapeutics S.A. Compounds which bind to cereblon, and use thereof
CN115504963A (zh) * 2021-06-22 2022-12-23 苏州开拓药业股份有限公司 一种c-Myc蛋白降解剂
WO2023025136A1 (zh) * 2021-08-27 2023-03-02 杭州格博生物医药有限公司 异吲哚啉酮化合物及其用途
WO2023138647A1 (zh) * 2022-01-19 2023-07-27 江苏恒瑞医药股份有限公司 一种含硫异吲哚啉类衍生物的晶型
WO2023220641A2 (en) 2022-05-11 2023-11-16 Juno Therapeutics, Inc. Methods and uses related to t cell therapy and production of same
WO2023220655A1 (en) 2022-05-11 2023-11-16 Celgene Corporation Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
CN115160211B (zh) * 2022-06-23 2023-11-03 温州大学 一种异吲哚啉酮类化合物的绿色合成方法
US11957759B1 (en) 2022-09-07 2024-04-16 Arvinas Operations, Inc. Rapidly accelerated fibrosarcoma (RAF) degrading compounds and associated methods of use
WO2024064646A1 (en) 2022-09-20 2024-03-28 Celgene Corporation Salts and solid forms of (s)- or racemic 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and methods of using the same
WO2024097905A1 (en) 2022-11-02 2024-05-10 Celgene Corporation Methods of treatment with t cell therapy and immunomodulatory agent maintenance therapy
WO2024104823A1 (en) 2022-11-16 2024-05-23 Basf Se New substituted tetrahydrobenzoxazepine

Family Cites Families (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4421865A (en) * 1981-06-08 1983-12-20 Standard Oil Company (Sohio) Selective hydrogen-deuterium interchange using ion exchange resins
US5001116A (en) 1982-12-20 1991-03-19 The Children's Medical Center Corporation Inhibition of angiogenesis
US4994443A (en) 1982-12-20 1991-02-19 The Children's Medical Center Corporation Inhibition of angiogenesis
ES8702440A1 (es) 1984-10-04 1986-12-16 Monsanto Co Un procedimiento para la preparacion de una composicion de polipeptido inyectable sustancialmente no acuosa.
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5149820A (en) * 1987-03-11 1992-09-22 Norsk Hydro A.S. Deuterated compounds
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
PH30995A (en) 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
AU1531492A (en) * 1991-02-14 1992-09-15 Rockefeller University, The Method for controlling abnormal concentration tnf alpha in human tissues
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
WO1994007498A1 (en) * 1992-10-07 1994-04-14 Sumitomo Pharmaceuticals Company, Limited Pharmaceutical composition for inhibiting tumor necrosis factor production
TW333456B (en) 1992-12-07 1998-06-11 Takeda Pharm Ind Co Ltd A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US6087324A (en) 1993-06-24 2000-07-11 Takeda Chemical Industries, Ltd. Sustained-release preparation
WO1995003009A1 (en) 1993-07-22 1995-02-02 Oculex Pharmaceuticals, Inc. Method of treatment of macular degeneration
WO1995003807A1 (en) 1993-07-27 1995-02-09 The University Of Sydney Treatment of age-related macular degeneration
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
IT1274549B (it) 1995-05-23 1997-07-17 Indena Spa Uso di flavanolignani per la preparazione di medicamenti ad attivita' antiproliferativa nei tumori dell'utero,dell'ovaio e del seno
AU6242096A (en) 1995-06-27 1997-01-30 Takeda Chemical Industries Ltd. Method of producing sustained-release preparation
TW448055B (en) 1995-09-04 2001-08-01 Takeda Chemical Industries Ltd Method of production of sustained-release preparation
JP2909418B2 (ja) 1995-09-18 1999-06-23 株式会社資生堂 薬物の遅延放出型マイクロスフイア
US5980945A (en) 1996-01-16 1999-11-09 Societe De Conseils De Recherches Et D'applications Scientifique S.A. Sustained release drug formulations
US5800819A (en) 1996-01-25 1998-09-01 National Institute For Pharmaceutical Research And Development Federal Ministry Of Science And Technology Piper guineense, pterocarpus osun, eugenia caryophyllata, and sorghum bicolor extracts for treating sickle cell disease
US6264970B1 (en) 1996-06-26 2001-07-24 Takeda Chemical Industries, Ltd. Sustained-release preparation
US5635517B1 (en) 1996-07-24 1999-06-29 Celgene Corp Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
CZ295762B6 (cs) 1996-07-24 2005-10-12 Celgene Corporation 2,6-Dioxopiperidiny, jejich soli a optické izomery, farmaceutické kompozice obsahující tyto sloučeniny a léčiva pro snížení hladiny TNFalfa obsahující tyto sloučeniny
HU228769B1 (en) 1996-07-24 2013-05-28 Celgene Corp Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha
US6281230B1 (en) 1996-07-24 2001-08-28 Celgene Corporation Isoindolines, method of use, and pharmaceutical compositions
US6419961B1 (en) 1996-08-29 2002-07-16 Takeda Chemical Industries, Ltd. Sustained release microcapsules of a bioactive substance and a biodegradable polymer
CA2217134A1 (en) 1996-10-09 1998-04-09 Sumitomo Pharmaceuticals Co., Ltd. Sustained release formulation
ES2221019T3 (es) 1996-10-31 2004-12-16 Takeda Chemical Industries, Ltd. Preparacion de liberacion mantenida.
US6197350B1 (en) 1996-12-20 2001-03-06 Takeda Chemical Industries, Ltd. Method of producing a sustained-release preparation
US5891474A (en) 1997-01-29 1999-04-06 Poli Industria Chimica, S.P.A. Time-specific controlled release dosage formulations and method of preparing same
DK1064277T3 (da) * 1998-03-16 2005-10-17 Celgene Corp 2-(2,6-dioxopiperidin-3-yl)isoindolinderivater, deres fremstilling og deres anvendelse som inhibitorer af inflammatoriske cytokiner
US6613358B2 (en) 1998-03-18 2003-09-02 Theodore W. Randolph Sustained-release composition including amorphous polymer
US6015803A (en) 1998-05-04 2000-01-18 Wirostko; Emil Antibiotic treatment of age-related macular degeneration
KR19990085365A (ko) 1998-05-16 1999-12-06 허영섭 지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법
US6225348B1 (en) 1998-08-20 2001-05-01 Alfred W. Paulsen Method of treating macular degeneration with a prostaglandin derivative
US6001368A (en) 1998-09-03 1999-12-14 Protein Technologies International, Inc. Method for inhibiting or reducing the risk of macular degeneration
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US7182953B2 (en) 1999-12-15 2007-02-27 Celgene Corporation Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders
DE60117486T2 (de) 2000-08-23 2006-11-16 General Electric Co. Spritzgegossene Keramik-Metallhalogenidbogenröhre mit einem nicht-konischen Ende
US6458810B1 (en) * 2000-11-14 2002-10-01 George Muller Pharmaceutically active isoindoline derivatives
US20030045552A1 (en) * 2000-12-27 2003-03-06 Robarge Michael J. Isoindole-imide compounds, compositions, and uses thereof
US20040190609A1 (en) 2001-11-09 2004-09-30 Yasuhiko Watanabe Moving picture coding method and apparatus
NZ572388A (en) 2002-05-17 2010-05-28 Celgene Corp Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases
US7323479B2 (en) 2002-05-17 2008-01-29 Celgene Corporation Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
US7393862B2 (en) 2002-05-17 2008-07-01 Celgene Corporation Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias
US7968569B2 (en) 2002-05-17 2011-06-28 Celgene Corporation Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
US7189740B2 (en) 2002-10-15 2007-03-13 Celgene Corporation Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
US20050203142A1 (en) 2002-10-24 2005-09-15 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
US20040091455A1 (en) 2002-10-31 2004-05-13 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration
US7563810B2 (en) 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
UA83504C2 (en) 2003-09-04 2008-07-25 Селджин Корпорейшн Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
EP1663223B1 (en) 2003-09-17 2014-01-01 The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services Thalidomide analogs as tnf-alpha modulators
US20050100529A1 (en) 2003-11-06 2005-05-12 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders
US20050143420A1 (en) 2003-12-02 2005-06-30 Moutouh-De Parseval Laure Methods and compositions for the treatment and management of hemoglobinopathy and anemia
US20050143344A1 (en) 2003-12-30 2005-06-30 Zeldis Jerome B. Methods and compositions using immunomodulatory compounds for the treatment and management of central nervous system disorders or diseases
CN1956718A (zh) 2004-03-22 2007-05-02 细胞基因公司 用于治疗和控制皮肤疾病和病症的含免疫调节化合物的组合物和使用方法
US20050222209A1 (en) 2004-04-01 2005-10-06 Zeldis Jerome B Methods and compositions for the treatment, prevention or management of dysfunctional sleep and dysfunctional sleep associated with disease
US20050239842A1 (en) 2004-04-23 2005-10-27 Zeldis Jerome B Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of pulmonary hypertension
AU2004319816A1 (en) 2004-05-05 2005-12-01 Celgene Corporation Method of using and compositions comprising immunomodulatory compounds for the treatment and management of myeloproliferative diseases
JP4943327B2 (ja) 2004-07-16 2012-05-30 シェーリング コーポレイション 炎症性障害の処置のためのヒダントイン誘導体
US7244759B2 (en) 2004-07-28 2007-07-17 Celgene Corporation Isoindoline compounds and methods of making and using the same
US7405237B2 (en) 2004-07-28 2008-07-29 Celgene Corporation Isoindoline compounds and methods of their use
BRPI0514865A (pt) 2004-09-03 2008-06-24 Celgene Corp processo para preparar um composto
KR20070086000A (ko) 2004-11-12 2007-08-27 셀진 코포레이션 기생충성 질병의 치료 및 관리를 위한 면역조절성 화합물을사용하는 방법 및 조성물
CN101102771A (zh) 2004-11-23 2008-01-09 细胞基因公司 用免疫调节化合物治疗和控制中枢神经系统损伤的方法和组合物
WO2006060507A2 (en) 2004-12-01 2006-06-08 Celgene Corporation Compositions comprising immunomodulatory compounds and the use thereof for the treatment of immunodeficiency disorders
ES2402204T3 (es) 2005-06-30 2013-04-29 Celgene Corporation Procedimientos para la preparación de compuestos de 4-amino-2-(2,6-dioxopiperidin-3-il)isoindolina-1,3-diona
UA91560C2 (ru) * 2005-08-31 2010-08-10 Селджин Корпорэйшн Соединения ряда изоиндолимидов, их композиция и применение
JO3235B1 (ar) 2006-05-26 2018-03-08 Astex Therapeutics Ltd مركبات بيررولوبيريميدين و استعمالاتها
ES2361584T3 (es) 2006-09-15 2011-06-20 Celgene Corporation Compuestos de n-metilaminometil-isoindol y composiciones que los comprenden y métodos que usan los mismos.
JP2010506937A (ja) 2006-10-19 2010-03-04 セルジーン・コーポレーション スピロヘータ及びその他の偏性細胞内細菌性疾患の治療及び管理のために免疫調節化合物を用いる方法及び組成物
EP3101017B1 (en) * 2007-03-20 2019-06-12 Celgene Corporation 4'-o-substituted isoindoline derivatives and compositions comprising and methods of using the same
LT3202460T (lt) * 2010-02-11 2019-10-10 Celgene Corporation Arilmetoksi izoindolino dariniai ir kompozicijos, apimantys ir jų panaudojimo būdus
WO2012027065A2 (en) 2010-08-27 2012-03-01 Celgene Corporation Combination therapy for treatment of disease
JP2013543009A (ja) 2010-11-18 2013-11-28 デューテリア ファーマシューティカルズ， インコーポレイテッド ３−ジュウテロ−ポマリドマイド
WO2012079022A1 (en) 2010-12-10 2012-06-14 Concert Pharmaceuticals, Inc. Substituted dioxopiperidinyl phthalimide derivatives
EP2699091B1 (en) 2011-03-28 2017-06-21 DeuteRx, LLC 2',6'-dioxo-3'-deutero-piperdin-3-yl-isoindoline compounds
CA2877736C (en) 2012-06-29 2021-12-07 Celgene Corporation Methods for determining drug efficacy using cereblon-associated proteins
NZ628077A (en) 2012-08-09 2017-04-28 Celgene Corp Treatment of immune-related and inflammatory diseases
US20140343058A1 (en) 2012-08-09 2014-11-20 Celgene Corporation Treatment of systemic lupus erythematosus
EP3949968A1 (en) 2012-08-09 2022-02-09 Celgene Corporation Methods of treating cancer using 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione
WO2014025978A1 (en) 2012-08-09 2014-02-13 Celgene Corporation Processes for the preparation of (s)-3-4-((4-(morpholinomethyl) benzyl)oxy)-1-oxoisoindolin-2-yl) piperidine-2,6-dione and pharmaceutically acceptable forms thereof
ES2885769T3 (es) 2012-08-09 2021-12-15 Celgene Corp Una forma sólida de clorhidrato de (s)-3-(4-((4-morpholinometil)bencil)oxi)-1-oxoisoindolin-2-il)piperidina-2,6-diona
US20150038511A1 (en) 2012-08-09 2015-02-05 Celgene Corporation Treatment of immune-related and inflammatory diseases
US9587281B2 (en) 2012-08-14 2017-03-07 Celgene Corporation Cereblon isoforms and their use as biomarkers for therapeutic treatment
CA2884103A1 (en) 2012-09-10 2014-03-13 Celgene Corporation Methods for the treatment of locally advanced breast cancer
US9695145B2 (en) 2013-01-22 2017-07-04 Celgene Corporation Processes for the preparation of isotopologues of 3-(4-((4- morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and pharmaceutically acceptable salts thereof
AU2014235273A1 (en) 2013-03-14 2015-07-09 Celgene Corporation Treatment of psoriatic arthritis using apremilast
KR102223060B1 (ko) 2013-04-17 2021-03-05 시그날 파마소티칼 엘엘씨 암 치료를 위한 TOR 키나제 억제제 및 ＩＭｉＤ 화합물을 포함하는 조합요법
UA117141C2 (uk) 2013-10-08 2018-06-25 Селджин Корпорейшн Склади (s)-3-(4-((4-(морфолінометил)бензил)оксі)-1-оксоізоіндолін-2-іл)піперидин-2,6-діону
BR112016012795A2 (pt) 2013-12-06 2017-08-08 Celgene Corp Métodos para a determinação da eficácia do fármaco para o tratamento de linfoma difuso de grandes células b, mieloma múltiplo e cânceres mieloides
US9415049B2 (en) 2013-12-20 2016-08-16 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
TWI745271B (zh) 2014-05-19 2021-11-11 美商西建公司 全身紅斑性狼瘡之治療
JP6640126B2 (ja) 2014-06-27 2020-02-05 セルジーン コーポレイション セレブロン及び他のｅ３ユビキチンリガーゼの立体構造の変化を誘導するための組成物及び方法
EP3188745A1 (en) 2014-08-15 2017-07-12 Celgene Corporation Dosage titration of apremilast for the treatment of diseases ameliorated by pde4 inhibition
WO2016060702A1 (en) 2014-10-13 2016-04-21 Celgene Corporaton Methods for treating solid tumors and the use of biomarkers as a predictor of clinical sensitivity to immunomodulatory therapies
PL3214081T3 (pl) 2014-10-30 2021-04-06 Kangpu Biopharmaceuticals, Ltd. Pochodna izoindoliny, półprodukt, sposób wytwarzania, kompozycja farmaceutyczna i ich zastosowanie
US9717745B2 (en) 2015-03-19 2017-08-01 Zhejiang DTRM Biopharma Co. Ltd. Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases

Also Published As

Publication number Publication date
HUE033009T2 (hu) 2017-11-28
US20160159768A1 (en) 2016-06-09
CN104693193B (zh) 2018-09-18
SG10202012179RA (en) 2021-01-28
SG183257A1 (en) 2012-09-27
MX367522B (es) 2019-08-26
CA2787823A1 (en) 2011-08-18
JP2017200944A (ja) 2017-11-09
US20200231567A1 (en) 2020-07-23
RU2012138709A (ru) 2014-03-20
US20130324518A1 (en) 2013-12-05
EP4289838A2 (en) 2023-12-13
US9822094B2 (en) 2017-11-21
US9309219B2 (en) 2016-04-12
AU2011215877A1 (en) 2012-08-16
US11414399B2 (en) 2022-08-16
HRP20191312T1 (hr) 2019-10-18
CA2787823C (en) 2018-04-10
EP2536706B1 (en) 2017-06-14
EP3202461A1 (en) 2017-08-09
US20160159772A1 (en) 2016-06-09
US8518972B2 (en) 2013-08-27
LT2536706T (lt) 2017-10-25
EP4289838A3 (en) 2024-03-13
KR20180000338A (ko) 2018-01-02
ES2730763T3 (es) 2019-11-12
UA114856C2 (uk) 2017-08-10
UA115220C2 (uk) 2017-10-10
JP2016106106A (ja) 2016-06-16
NZ717149A (en) 2017-06-30
ES2738776T3 (es) 2020-01-27
AU2011215877B2 (en) 2013-11-07
US20190135780A1 (en) 2019-05-09
JP6270944B2 (ja) 2018-01-31
RS58523B1 (sr) 2019-04-30
CY1119177T1 (el) 2018-02-14
KR20130010888A (ko) 2013-01-29
MX337169B (es) 2016-02-16
NI201200132A (es) 2013-04-22
EP3599236B1 (en) 2023-08-23
SI3202461T1 (sl) 2019-05-31
PL3202460T3 (pl) 2019-12-31
US20220411402A1 (en) 2022-12-29
HRP20190368T1 (hr) 2019-04-19
CY1121729T1 (el) 2020-07-31
PH12014501082A1 (en) 2015-09-28
HRP20171078T1 (hr) 2017-10-06
CO6571916A2 (es) 2012-11-30
LT3202460T (lt) 2019-10-10
IL220992A (en) 2016-11-30
ES2713482T3 (es) 2019-05-22
CN102822165B (zh) 2015-02-25
KR101931468B1 (ko) 2018-12-20
AR081058A1 (es) 2012-06-06
US10669257B2 (en) 2020-06-02
US20180037567A1 (en) 2018-02-08
EP3202460B1 (en) 2019-06-12
JP2013519675A (ja) 2013-05-30
EP3202461B1 (en) 2018-12-26
PL3202461T3 (pl) 2019-07-31
CY1121858T1 (el) 2020-10-14
IL248843B (en) 2019-12-31
JP2016172746A (ja) 2016-09-29
JP2017031165A (ja) 2017-02-09
US10189814B2 (en) 2019-01-29
EP3599236A1 (en) 2020-01-29
ME03441B (me) 2020-01-20
HUE044652T2 (hu) 2019-11-28
NZ601289A (en) 2014-10-31
WO2011100380A1 (en) 2011-08-18
PT2536706T (pt) 2017-07-20
SI2536706T1 (sl) 2017-10-30
RS59275B1 (sr) 2019-10-31
CR20120414A (es) 2012-10-31
CN102822165A (zh) 2012-12-12
ECSP12012098A (es) 2012-10-30
DK3202461T3 (en) 2019-03-18
RS56232B1 (sr) 2017-11-30
SI3202460T1 (sl) 2019-10-30
NZ700054A (en) 2016-03-31
EP3106460A1 (en) 2016-12-21
PL2536706T3 (pl) 2017-10-31
RU2567753C2 (ru) 2015-11-10
ME02766B (me) 2018-01-20
HUE042011T2 (hu) 2019-06-28
US9828361B2 (en) 2017-11-28
ES2956743T3 (es) 2023-12-27
AU2011215877C1 (en) 2017-01-19
US20110196150A1 (en) 2011-08-11
CN104693193A (zh) 2015-06-10
EP2536706A1 (en) 2012-12-26
LT3202461T (lt) 2019-04-25
IL248843A0 (en) 2017-01-31
JP6215976B2 (ja) 2017-10-18
PT3202461T (pt) 2019-03-19
TR201903027T4 (tr) 2019-03-21
DK2536706T3 (en) 2017-08-14
ES2638517T3 (es) 2017-10-23
PH12014501082B1 (en) 2015-09-28
EP3106460B1 (en) 2019-04-10
EP3202460A1 (en) 2017-08-09
DK3202460T3 (da) 2019-07-29
MX2012009237A (es) 2012-08-23
PT3202460T (pt) 2019-08-05
KR101812356B1 (ko) 2017-12-26

Similar Documents

Publication Publication Date Title
HRP20190368T1 (hr) Derivati arilmetoksi izoindolina i pripravci koji ih sadrže te postupci njihove uporabe
EP2536756A4 (en) HSA-RELATED COMPOSITIONS AND USE PROCESSES
EP2584897A4 (en) COMPOSITIONS CONTAINING RESVERATROL AND METHODS OF USE
EP2569425A4 (en) ENDORIBONUCLEASE COMPOSITIONS AND METHOD FOR THEIR USE
EP2603201A4 (en) LIPOSOME COMPOSITIONS AND USE METHOD THEREFOR
HK1175947A1 (en) Pharmaceutical compositions and methods of making same
EP2596112A4 (en) ACETYCYSTEIN COMPOSITIONS AND USE METHOD THEREFOR
IL222969A0 (en) Sweetener compositions and methods of preparing the same
EP2629742A4 (en) HAIR CARE COMPOSITIONS AND RELATED METHODS
EP2588117A4 (en) STABLE ANTISEPTIC COMPOSITIONS AND METHODS
IL220715A0 (en) Nutritive compositions and methods of using same
HK1201451A1 (en) Compositions and methods
EP2566485A4 (en) IMMUNOSTIMULATORY COMPOSITIONS AND METHODS OF USE THEREOF
GB201018650D0 (en) Methods and compositions
AU2010901846A0 (en) Therapeutic methods and compositions
GB201018651D0 (en) Methods and compositions
GB201010083D0 (en) Compositions and methods
GB201009767D0 (en) Compositions and methods
GB201003741D0 (en) Methods and therapeutic compositions
AU2010901845A0 (en) Cosmetic methods and compositions